List of Corcept Therapeutics patents

Patents where

Current Assignee

Name

Corcept Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11327083 Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome	Patent 11327083 was granted and assigned to Corcept Therapeutics on May, 2022 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	11327083	May 10, 2022
‌ US Patent 11464764 Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound	Patent 11464764 was granted and assigned to Corcept Therapeutics on October, 2022 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	11464764	October 11, 2022
‌ US Patent 9996672 Systems and methods of treatment using intervention and tasking determination	Patent 9996672 was granted and assigned to Corcept Therapeutics on June, 2018 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	9996672	June 12, 2018
‌ US Patent 10117852 Glucocorticoid receptor modulators to treat pancreatic cancer	Patent 10117852 was granted and assigned to Corcept Therapeutics on November, 2018 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	10117852	November 6, 2018
‌ US Patent 10213414 Glucocorticoid receptor modulators to treat pancreatic cancer	Patent 10213414 was granted and assigned to Corcept Therapeutics on February, 2019 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	10213414	February 26, 2019
‌ US Patent 11058670 Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator	Patent 11058670 was granted and assigned to Corcept Therapeutics on July, 2021 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	11058670	July 13, 2021
‌ US Patent 11202784 Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency	Patent 11202784 was granted and assigned to Corcept Therapeutics on December, 2021 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	11202784	December 21, 2021
‌ US Patent 9829495 Method for differentially diagnosing ACTH-dependent Cushing's syndrome	Patent 9829495 was granted and assigned to Corcept Therapeutics on November, 2017 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	9829495	November 28, 2017
‌ US Patent 10568880 Glucocorticoid receptor modulators to treat cervical cancer	Patent 10568880 was granted and assigned to Corcept Therapeutics on February, 2020 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	10568880	February 25, 2020
‌ US Patent 11610666 Systems and methods of managing treatment of a chronic condition by symptom tracking	Patent 11610666 was granted and assigned to Corcept Therapeutics on March, 2023 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	11610666	March 21, 2023
‌ US Patent 10898478 Glucocorticoid receptor modulators to treat cervical cancer	Patent 10898478 was granted and assigned to Corcept Therapeutics on January, 2021 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	10898478	January 26, 2021
‌ US Patent 10413540 Glucocorticoid receptor modulators to treat cervical cancer	Patent 10413540 was granted and assigned to Corcept Therapeutics on September, 2019 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	10413540	September 17, 2019
‌ US Patent 10047082 Octahydro fused azadecalin glucocorticoid receptor modulators	Patent 10047082 was granted and assigned to Corcept Therapeutics on August, 2018 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	10047082	August 14, 2018
‌ US Patent 9943505 Glucocorticoid receptor modulators to treat pancreatic cancer	Patent 9943505 was granted and assigned to Corcept Therapeutics on April, 2018 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	9943505	April 17, 2018
‌ US Patent 11560379 Octahydro fused azadecalin glucocorticoid receptor modulators		Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	11560379	January 24, 2023
‌ US Patent 11760731 Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators	Patent 11760731 was granted and assigned to Corcept Therapeutics on September, 2023 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	11760731	September 19, 2023
‌ US Patent 9943526 Optimizing mifepristone levels for cushing's patients	Patent 9943526 was granted and assigned to Corcept Therapeutics on April, 2018 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	9943526	April 17, 2018
‌ US Patent 11370789 Octahydro fused azadecalin glucocorticoid receptor modulators	Patent 11370789 was granted and assigned to Corcept Therapeutics on June, 2022 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	11370789	June 28, 2022
‌ US Patent 11684612 Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator	Patent 11684612 was granted and assigned to Corcept Therapeutics on June, 2023 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	11684612	June 27, 2023
‌ US Patent 11285145 Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4	Patent 11285145 was granted and assigned to Corcept Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	11285145	March 29, 2022
‌ US Patent 10195214 Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors	Patent 10195214 was granted and assigned to Corcept Therapeutics on February, 2019 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	10195214	February 5, 2019
‌ US Patent 10456392 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators	Patent 10456392 was granted and assigned to Corcept Therapeutics on October, 2019 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	10456392	October 29, 2019
‌ US Patent 9273047 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators	Patent 9273047 was granted and assigned to Corcept Therapeutics on March, 2016 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	9273047	March 1, 2016
‌ US Patent 11542238 Pyrimidine cyclohexenyl glucocorticoid receptor modulators	Patent 11542238 was granted and assigned to Corcept Therapeutics on January, 2023 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	11542238	January 3, 2023
‌ US Patent 9707223 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators	Patent 9707223 was granted and assigned to Corcept Therapeutics on July, 2017 by the United States Patent and Trademark Office.	Corcept Therapeutics	Corcept Therapeutics	United States Patent and Trademark Office	9707223	July 18, 2017

...

Results per page:

106 results

0 selected

106 results

0 selected